A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR

Area of Science:

• Marine natural products chemistry
• Molecular biology
• Oncology

Background:

• Non-Small Cell Lung Cancer (NSCLC) pathogenesis involves deregulated kinases, necessitating multi-target inhibitors.
• Current multi-target kinase inhibitors have limitations in addressing diverse NSCLC mutations and pathways.

Purpose of the Study:

• To identify and characterize novel reversible multi-target kinase inhibitors for NSCLC treatment.
• To evaluate the efficacy of ZWM026, an indolocarbazoles analogue, against various NSCLC cell lines and kinase targets.

Main Methods:

• Screening of mangrove-derived compounds for kinase inhibitory activity.
• In vitro kinase assays to determine selectivity and reversibility against EGFR mutants and other kinases (HER2, HER3, HER4, RET).
• Assessment of ZWM026's effects on NSCLC cell apoptosis and synergy with cisplatin in NCI-H1975 cells.

Main Results:

• ZWM026, an indolocarbazoles analogue, demonstrated selective and reversible inhibition of T790M mutant EGFR over wild-type EGFR.
• Simultaneous inhibition of HER2, HER3, HER4, and RET kinases was observed, distinct from existing multi-target inhibitors.
• ZWM026 exhibited potent activity against gefitinib-sensitizing, non-sensitizing, and rare EGFR mutant NSCLC cells, inducing apoptosis and showing synergistic effects with cisplatin.

Conclusions:

• ZWM026 represents a novel reversible multi-target inhibitor with significant potential for NSCLC drug development.
• Its unique inhibitory profile and synergistic activity suggest it could overcome resistance mechanisms and improve therapeutic outcomes in NSCLC.